X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aventis Pharma: OPM disappointment continues… - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 31, 2002

    Aventis Pharma: OPM disappointment continues…

    Aventis Pharma, has reported nearly 13% topline growth for 3QFY03 on the back of strong performance of its strategic brands and jump in exports to CIS countries. The results for the relevant period under review are on a merged basis with RPR (Rhone Poulenc Rorer) and hence not exactly comparable on a like to like basis with the previous year numbers.

    (Rs m) 3QFY02 3QFY03 % Change 9mFY02 9mFY03 % Change
    Net Sales 1,412 1,592 12.7% 3,802 4,516 18.8%
    Other Income 26 31 19.2% 81 72 -11.1%
    Expenditure 1,141 1,328 16.4% 3,097 3,810 23.0%
    Operating Profit (EBDIT) 271 264 -2.6% 705 706 0.1%
    Operating Profit Margin (%) 19.2% 16.6%   18.5% 15.6%  
    Interest 4 1 -75.0% 15 4 -73.3%
    Depreciation 38 38 0.0% 113 112 -0.9%
    Profit before Tax 255 256 0.4% 658 662 0.6%
    Extraordinary Expenses (VRS) (39) (5) - 31 (4) -
    Tax 64 85 32.8% 213 215 0.9%
    Profit after Tax/(Loss) 152 166 9.2% 476 443 -6.9%
    Net profit margin (%) 10.8% 10.4%   12.5% 9.8%  
    No. of Shares (eoy) (m) 23 23   23 23  
    Diluted Earnings per share* 26.4 28.9   27.6 25.7  
    P/E (at current price)   11.1     12.5  
    (*- annualised)            

    Domestic sales have grown by 9% from Rs 1.2 bn to Rs 1.3 bn including Rs 96 m from merger of RPR business. The performance has been on the back of strong growth in strategic products such as cardace (20% - cardiovascular), Amaryl (34% - anti-diabetes) and Targocid (29% - anti-infective). In addition, Clexane, acquired from RPR grew by a strong 41% during the quarter. Formulations exports sales (mainly to CIS countries) have recorded a growth of more than 20%.The company’s Ankleshwar unit is being used by the parent as a sourcing base for bulk drugs like Ramipril and Articaine. Further, the company has indicated that the parent has initiated steps to import Daonil formulations (a leading product in anti-diabetic segment) from India. Exports currently account for about 20% of the company’s revenues with Russia and CIS countries accounting for about 85% of the total export pie.

    Despite strong sales growth, operating margins have been playing a spoilsport. Operating margins dropped from 19.2% in 3QFY02 to 16.6% this September quarter. Though the company's products enjoy a strong brand equity, it faces stiff competition from generic products. Raw material consumption to sales ratio indicates a drop in realisations for the company's products. Further, operating margins have also been affected on account of front loading of marketing expenses for products (Lantus and Actonel) expected to be launched in the next year. The company has stated that they expect these product promotion expenses to decline in the coming quarters.

    Cost break-up
    (Rs m) 3QFY02 3QFY03 % Change 9mFY02 9mFY03 % Change
    Raw material 744 886 19.1% 1,949 2,425 24.4%
    Staff cost 114 119 4.4% 329 383 16.4%
    Others 283 323 14.1% 819 1,002 22.3%
    Total Expenditure 1,141 1,328 16.4% 3,097 3,810 23.0%

    At the current market price of Rs 320, the stock trades at 9.7x our expected earnings for FY03. On the back of the support extended by the parent, Aventis has transformed itself from a company catering mainly to the anti-infectives and pain management segments to a company with a strong and focused portfolio of products for the chronic and critical-care therapeutic segments. The strategic brands continue to grow at healthy growth rates and this is expected to offset the impact of the laggards in its folio. This portfolio bias is expected to continue in the foreseeable future as well. Notwithstanding some unclarity on the impact of the DPCO order, valuations of the company are attractive on a peer comparision basis.

     

     

    Equitymaster requests your view! Post a comment on "Aventis Pharma: OPM disappointment continues…". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    SANOFI INDIA SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK SANOFI INDIA

    • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    SANOFI INDIA - J.B.CHEMICALS COMPARISON

    Compare Company With Charts

    COMPARE SANOFI INDIA WITH

    MARKET STATS